© 2024 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
Brielle Benyon, Assistant Managing Editor for CURE®, has been with MJH Life Sciences since 2016. She has served as an editor on both CURE and its sister publication, Oncology Nursing News. Brielle is a graduate from The College of New Jersey. Outside of work, she enjoys spending time with family and friends, CrossFit and wishing she had the grace and confidence of her toddler-aged daughter.
Here is a roundup of cancer treatments that were approved by the FDA in the spring of 2022 that patients may have missed.
Several cancer treatments received approvals from the Food and Drug Administration (FDA) in the spring.
The FDA approvals were indicated for drug combinations to treat solid tumors with certain genetic characteristics, as well as a biosimilar to treat neutropenia (lower-than-normal levels of neutrophils, which is a type of white blood cell).
Here, CURE® provides a rundown of the newer cancer therapies that the FDA approved this spring:
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Related Content: